Roche Holding AG RHHBY
59.00 USD -0.52 (-0.87%)
Regular-session close
59.07 Day range 59.15
47.05 52-week range 61.75
- YTD
- +14.41%
- 1 year
- +23.12%
5D -1.14 (-1.90%)
- Market cap
- 376.07B
- EPS (ttm)
- 2.41
- P/E ratio
- 24.48
- YTD return
- +14.41%
- 1-year return
- +23.12%
- Volume
- 791
- Avg volume
- 1.56M
- Open
- 59.07
- Previous close
- 59.52
- Day's range
- 59.07 – 59.15
- 52-week range
- 47.05 – 61.75
- Earnings date
- Feb 4, 2027
Next earnings
Feb 4, 2027
Expected Feb 4, 2027. Consensus EPS estimate 1.49.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 4, 2027 | Dec 30, 2026 | 1.49 | — | — | — |
| Jul 23, 2026 | Jun 30, 2026 | 1.58 | 1.66 | +0.08 | +5.06% |
| Jan 29, 2026 | Dec 31, 2025 | 1.35 | 1.36 | +0.01 | +0.74% |
| Jul 24, 2025 | Jun 30, 2025 | 1.62 | 1.74 | +0.12 | +7.41% |
| Jan 30, 2025 | Dec 31, 2024 | 1.17 | 1.18 | +0.01 | +0.85% |
| Jul 22, 2024 | Jun 30, 2024 | 1.30 | 1.43 | +0.13 | +10.00% |
News
Merck Ends Nemtabrutinib Development: What's Next for Its Pipeline?
RHHBY Secures FDA Approval for Breast Cancer Treatment Reported November 16, Roche Receives FDA Approval For Wiserdley In Combination With Everolimus For Breast Cancer Treatment
Roche Secures First U.S. Approval for New Breast-Cancer Pill
FDA Approves Genentech's WILSERDLY (Giredestrant), a Next-Generation Oral SERD, for ER-Positive, ESR1-Mutated Advanced Breast Cancer
FDA approves Roche's Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer
US FDA approves Roche's oral treatment for advanced breast cancer
Roche receives FDA De Novo authorization for cobas® pro i 601 platform with Ionify® Gabapentin assay, advancing automated mass spectrometry for routine clinical laboratories
Chances of Jensen Huang returning to Nvidia 'very slim': David Roche
Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+/HER2- Advanced Breast Cancer
Your note
Sign in to keep a note on RHHBY — it syncs with the Stock Master app.
